Genetic evaluation of dermatoglyphics patterns with recurrent pregnancy loss patients in Chennai
Author(s):
Sharmila D, Venkatesan L, Dharmarajan P and N Jothi Narendiran
Abstract:
Dermatoglyphics is the scientific study of papillary ridges in the palm of the hand and fingers and soles of the feet and toes. The dermal ridges and the configuration which is once formed are not affected by age, development and environmental changes in the post-natal life and so, it has the potential to predict various genetic and acquired disorders with a genetic influence. Recurrent pregnancy loss also called recurrent miscarriage, spontaneous abortion; habitual abortion is defined as consecutive loss of three or more pregnancies before five months of gestation. Most of the factors responsible for recurrent pregnancy loss can be genetic abnormalities, uterine abnormalities, endocrine factors, immunological factors, lifestyle changes and hormonal imbalance. The aim of this study was to determine the dermatoglyphic features of patients with recurrent pregnancy loss compare to women with no genetic abnormality. Dermatoglyphic patterns of 100 females (cases) and 100 (control) were analyzed to detect any relation between recurrent pregnancy loss cases and dermatoglyphics. All the patients were asked and got their palmer dermatoglyphic impression on plain white A4 paper used the ink method. Recurrent pregnancy loss cases 5.65% were found to have Radial loops, 52.72% were found to have Ulnar loops, 30.18%were found to have whorls and 11.45% were found to have Arches. The result obtained from the controls 5.15% were found to have Radial loops, 60.15% were found to have Ulnar loops,28.25%were found to have whorls and 6.45% were found to have Arches. There is very less study done on dermatoglyphic features in recurrent pregnancy loss. Dermatoglyphics is an upcoming integral part of forensic science and medicine.
How to cite this article:
Sharmila D, Venkatesan L, Dharmarajan P, N Jothi Narendiran. Genetic evaluation of dermatoglyphics patterns with recurrent pregnancy loss patients in Chennai. Pharma Innovation 2018;7(10):157-159.